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Mitochondrial energy metabolism  
in heart failure: a question of balance
Janice M. Huss1,2 and Daniel P. Kelly1,2,3,4
1Center for Cardiovascular Research and 2Department of Medicine, 3Department of Molecular Biology & Pharmacology, and  
4Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
The mitochondrion serves a critical role as a platform for energy transduction, signaling, and cell death pathways 
relevant to common diseases of the myocardium such as heart failure. This review focuses on the molecular regula-
tory events and downstream effector pathways involved in mitochondrial energy metabolic derangements known 
to occur during the development of heart failure.
Introduction
All cellular processes are driven by ATP-dependent pathways. The 
heart has perpetually high energy demands related to the main-
tenance of specialized cellular processes, including ion transport, 
sarcomeric function, and intracellular Ca2+ homeostasis. Myocar-
dial workload (energy demand) and energy substrate availability 
(supply) are in continual flux, yet the heart has a limited capac-
ity for substrate storage. Thus, ATP-generating pathways must 
respond proportionately to dynamic fluctuations in physiologi-
cal demands and fuel delivery. The time frame of such metabolic 
regulatory responses ranges from seconds to minutes (acute) or 
hours to days (chronic) and involves regulation at multiple levels, 
including allosteric control of enzyme activity via metabolic inter-
mediates, signal transduction events, and the regulation of genes 
encoding rate-limiting enzymes and proteins.
Metabolic regulation is inextricably linked with cardiac func-
tion. This metabolism-function relationship is relevant to dis-
eases that lead to cardiac hypertrophy and heart failure. The 
progression to heart failure of any cause is associated with a 
gradual but progressive decline in the activity of mitochondrial 
respiratory pathways leading to diminished capacity for ATP 
production. Reduced capacity for energy transduction leads 
to secondary dysregulation of cellular processes critical for 
cardiac pump function, including Ca2+ handling and contrac-
tile function, which results in a downward spiral of increased 
energy demand and diminished function. Evidence has emerged 
that energy deficiency can be a cause and an effect of heart fail-
ure. Cardiac metabolic regulatory events may also be adaptive 
in certain disease states. For example, in the ischemic heart, a 
reduction in mitochondrial oxidative capacity serves to reduce 
oxygen consumption in the context of limited O2 availability. 
Many of the metabolic regulatory events that dictate fuel selec-
tion and capacity for ATP production in the normal and fail-
ing heart occur at the level of gene expression. The consequence 
of specific metabolic gene regulatory events as adaptive versus 
maladaptive in the context of myocardial disease is an area of 
intense investigation.
The purposes of this review are to provide a brief overview of 
cardiac energy metabolic pathways with emphasis on the mito-
chondrion, to describe the gene regulatory circuitry involved in 
the regulation of cardiac mitochondrial energy metabolism in 
the normal heart, to summarize the current knowledge about 
how this metabolic regulatory network is altered during the 
development of heart failure, and to review the evidence that 
links altered energy metabolism to the development of heart 
failure. Emphasis will be given to gene regulatory mechanisms 
and upstream signaling pathways.
Cardiac energy metabolic pathways
Oxidation of fatty acids (FAs) and glucose in mitochondria 
accounts for the vast majority of ATP generation in the healthy 
adult heart (1, 2). FAs are the preferred substrate in the adult myo-
cardium, supplying about 70% of total ATP (3–5). FAs derived 
from circulating triglyceride-rich lipoproteins and albumin-
bound nonesterified FAs are oxidized in the mitochondrial matrix 
by the process of FA β-oxidation (FAO), whereas pyruvate derived 
from glucose and lactate is oxidized by the pyruvate-dehydroge-
nase (PDH) complex, localized within the inner mitochondrial 
membrane (Figure 1). Acetyl-CoA, derived from both pathways, 
enters the tricarboxylic acid (TCA) cycle. Reduced flavin adenine 
dinucleotide (FADH2) and NADH are generated via substrate flux 
through the β-oxidation spiral and the TCA cycle, respectively. 
The reducing equivalents enter the electron transport chain, 
producing an electrochemical gradient across the mitochondrial 
membrane that drives ATP synthesis in the presence of molecular 
oxygen (oxidative phosphorylation).
Mitochondrial enzymes are encoded by both nuclear and 
mitochondrial genes (reviewed in ref. 6). All of the enzymes 
of β-oxidation and the TCA cycle, and most of the subunits of 
electron transport/oxidative phosphorylation, are encoded by 
nuclear genes. The mitochondrial genome is comprised of 1 cir-
cular double-stranded chromosome that encodes 13 electron 
transport chain subunits within complexes I, III, and IV (7). 
Since mitochondrial number and function require both nuclear 
and mitochondrial-encoded genes, coordinated mechanisms 
exist to regulate the 2 genomes and determine overall cardiac 
oxidative capacity. In addition, distinct pathways exist to coor-
dinately regulate nuclear genes encoding component mito-
chondrial pathways.
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The transcriptional network regulating cardiac 
mitochondrial biogenesis and respiratory function
PGC-1α: an inducible integrator of transcriptional circuits regulating mito-
chondrial biogenesis and function. The PPARγ coactivator-1 (PGC-1) 
family of transcriptional coactivators is involved in regulating 
mitochondrial metabolism and biogenesis. PGC-1α was the first 
member discovered through its functional interaction with the 
nuclear receptor PPARγ in brown adipose tissue (BAT), a mito-
chondrial-rich tissue involved in thermogenesis (8). Two PGC-1α– 
related coactivators, PGC-1β (also called PERC) and PGC-1–relat-
ed coactivator (PRC), have since been identified (9–11). PRC is ubi-
quitously expressed and coactivates transcription factors involved 
in mitochondrial biogenesis; however, to date there is no direct 
empirical evidence that PRC drives or is necessary for mitochon-
drial biogenesis (9, 12). PGC-1α and PGC-1β share some regula-
tory overlap. Both are preferentially expressed in tissues with high 
oxidative capacity, such as heart, slow-twitch skeletal muscle, and 
BAT, where they serve critical roles in the regulation of mitochon-
drial functional capacity (8, 10, 13–15). PGC-1α regulates addi-
tional metabolic pathways, including hepatic gluconeogenesis and 
skeletal muscle glucose uptake (16–18). Based on its tissue expres-
sion pattern, PGC-1β probably plays a role in regulating energy 
metabolism in the heart, although its precise role in the normal 
heart and in mediating alterations in energy metabolism observed 
in heart failure has not been investigated.
PGC-1α is distinct from other PGC-1 family members, indeed 
from most coactivators, in its broad responsiveness to develop-
mental alterations in energy metabolism and physiological and 
pathological cues at the level of expression and transactivation. In 
the heart, PGC-1α expression increases at birth coincident with 
an increase in cardiac oxidative capacity and a perinatal shift from 
reliance on glucose metabolism to the oxidation of fats for energy 
(19). PGC-1α is induced by physiological stimuli that increase ATP 
demand and stimulate mitochondrial oxidation, including cold 
exposure, fasting, and exercise (8, 19–23). Activation of the PGC-1α 
regulatory cascade increases cardiac mitochondrial oxidative capac-
ity in the heart. In cardiac myocytes in culture, PGC-1α increases 
mitochondrial number, upregulates expression of mitochondrial 
enzymes, and increases rates of FA oxidation and coupled respi-
ration (19, 24). A mouse cardiac-specific conditional transgenic 
expression system was used to demonstrate that PGC-1α triggers 
mitochondrial biogenesis in vivo in a developmental stage–depen-
dent manner: permissive during the neonatal period but less so in 
the adult heart (25). In summary, PGC-1α is an inducible coactiva-
tor that coordinately regulates cardiac fuel selection and mitochon-
drial ATP-producing capacity.
How does PGC-1α exert its pleiotropic effects on mitochondrial 
biogenesis and respiratory function? Recent work by several labo-
ratories has provided insight into the downstream transcriptional 
regulatory circuits through which PGC-1α mediates its effects 
(Figure 2) (6). PGC-1α activates expression of nuclear respiratory fac-
tor-1 (NRF-1) and NRF-2 and directly coactivates NRF-1 on its target 
gene promoters (13). NRF-1 and NRF-2 regulate expression of mito-
chondrial transcription factor A (Tfam), a nuclear-encoded transcrip-
tion factor that binds regulatory sites on mitochondrial DNA and is 
essential for replication, maintenance, and transcription of the mito-
chondrial genome (26–28). Furthermore, NRF-1 and NRF-2 regulate 
the expression of nuclear genes encoding respiratory chain subunits 
and other proteins required for mitochondrial function (29, 30).
PGC-1α coactivates the PPAR and ERR nuclear receptors, critical regula-
tors of myocardial FA utilization. PGC-1α regulates genes involved in 
the cellular uptake and mitochondrial oxidation of FAs through 
Figure 1
Pathways involved in cardiac energy metabo-
lism. FA and glucose oxidation are the main 
ATP-generating pathways in the adult mam-
malian heart. Acetyl-CoA derived from FA 
and glucose oxidation is further oxidized in 
the TCA cycle to generate NADH and FADH2, 
which enter the electron transport/oxidative 
phosphorylation pathway and drive ATP syn-
thesis. Genes encoding enzymes involved at 
multiple steps of these metabolic pathways 
(i.e., uptake, esterification, mitochondrial 
transport,and oxidation) are transcriptionally 
regulated by PGC-1α with its nuclear recep-
tor partners, including PPARs and ERRs (blue 
text). Glucose uptake/oxidation and electron 
transport/oxidative phosphorylation pathways 
are also regulated by PGC-1α via other tran-
scription factors, such as MEF-2 and NRF-1. 
Cyt c, cytochrome c.
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direct coactivation of PPARs and estrogen-related receptors (ERRs) 
(Figure 2) (31–34). PPARs are FA-activated members of the nuclear 
receptor superfamily of transcription factors that serve as central 
regulators of cardiac FA metabolism. There are 3 PPAR isoforms 
(α, β/δ, and γ); PPARα and PPARβ are the primary regulators of FA 
metabolism in the heart. PPARs function by binding as obligate 
heterodimers with the retinoid X receptor α (RXRα) and recruit-
ing coactivators, including PGC-1α, in response to direct binding 
and activation by FAs and their derivatives, which serve as ligands. 
PPARα regulates genes involved in virtually every step of cardiac FA 
utilization (reviewed in ref. 35). PPARα-null mice have reduced car-
diac expression of genes involved in the cellular uptake, mitochon-
drial transport, and mitochondrial (and peroxisomal) oxidation of 
FAs (36–38). Myocardial FA uptake and oxidation rates are decreased 
in these mice, while glucose oxidation rates are increased (39). 
PPARα-null mice have also provided evidence that PPARα serves 
an important homeostatic function in the context of physiological 
and dietary stressors. When subjected to fasting or pharmacological 
inhibition of FAO, PPARα–/– mice develop massive cardiac myocyte 
lipid accumulation and hepatic steatosis (40, 41). These results have 
defined PPARα as an important regulator of myocardial energy sub-
strate preference and FAO capacity within the PGC-1α transcrip-
tional regulatory cascade.
In contrast to the biological function of PPARα, that of PPARβ 
(also known as PPARδ) in the heart has not been extensively 
studied. However, recent evidence indicates that cardiac PPARβ 
target genes significantly overlap with those of PPARα. PPARβ 
selective ligands induce mitochondrial FAO enzyme genes and 
increase palmitate oxidation rates in cardiac myocytes from both 
wild-type and PPARα–/– mice (42, 43). Consistent with findings 
from activation studies, cardiac-specific deletion of the PPARβ 
gene results in reduced expression of FAO enzyme genes and 
diminished palmitate oxidation rates, which is similar to what 
occurs in PPARα-null mice (44). In contrast to PPARα–/– mice, 
however, cardiac-specific PPARβ-null mice do not exhibit a fast-
ing-induced phenotype. Rather, PPARβ-deficient mice develop 
a cardiomyopathy under basal conditions. Collectively, these 
results suggest that, although PPARα and PPARβ drive similar 
gene targets, PPARβ probably serves to regulate basal metabo-
lism whereas PPARα is perhaps more important in the response 
to physiological conditions that increase FA delivery.
ERRs are a subfamily of orphan nuclear receptors for which a 
role in cardiac energy metabolism has recently been described. 
There are 3 members of the ERR family: ERRα, ERRβ, and ERRγ 
(45–47). Cardiac ERRα expression increases dramatically follow-
ing birth, coincident with the switch to FAs as an energy substrate 
and the upregulation of PPARα and PGC-1α and of enzymes 
involved in FA uptake and mitochondrial oxidation (33, 48). Both 
ERRα and ERRγ are directly coactivated by PGC-1α while ERRα is 
further regulated by PGC-1α at the gene expression level (33, 34, 
49, 50). Recent evidence suggests that ERRα cross-regulates other 
transcription factors within the PGC-1α network. In cardiac myo-
cytes, ERRα activates expression of many known PPARα and NRF 
target genes involved in cellular FA utilization and mitochondrial 
electron transport/oxidative phosphorylation, respectively (24). 
This apparently overlapping function was recently shown to 
occur, in part, via direct transactivation of the PPARα and Gabpa 
(NRF-2 subunit) gene promoters. (Figure 2) (24, 51). In addition, 
ERRα cooperates with NRF-1 and NRF-2 to regulate mitochon-
drial biogenesis and expression of oxidative phosphorylation 
enzyme genes (51, 52). Collectively, these results support a role 
for ERRα as an amplifier of cardiac oxidative energy metabolism 
downstream of PGC-1α (Figure 2).
Signaling pathways trigger changes in mitochondrial function through 
the PGC-1α regulatory cascade. How do PGC-1α and its transcrip-
tion factor partners receive input from physiological and patho-
logical stimuli? Insights into the physiological responsiveness 
of the PGC-1α pathway come from identification of signal 
transduction pathways that modulate the activity of PGC-1α and 
its downstream partners (Figure 2). PGC-1α is upregulated in 
response to β-adrenergic signaling, consistent with the involve-
ment of this pathway in thermogenesis (8, 53). The stress-acti-
vated MAPK p38 activates PGC-1α by both increasing PGC-1α 
protein stability and promoting dissociation of a repressor 
(21, 54, 55). p38 also increases mitochondrial FAO through selec-
tive activation of the PGC-1α partner, PPARα (56). Conversely, 
the ERK-MAPK pathway inactivates the PPARα/RXRα complex 
via direct phosphorylation (57). Therefore, distinct limbs of the 
MAPK pathway exert opposing regulatory influences on the 
PGC-1α cascade. Recently, NO has emerged as a novel signaling 
molecule proposed to integrate pathways involved in regulating 
mitochondrial biogenesis. NO induces mitochondrial prolif-
Figure 2
PGC-1α is an integrator of the transcriptional network regulating 
mitochondrial biogenesis and function. Numerous signaling path-
ways, including Ca2+-dependent, NO, MAPK, and β-adrenergic 
pathways (β3/cAMP), activate the PGC-1α directly by increasing 
either PGC-1α expression or activity. Additionally, the p38MAPK 
pathway selectively activates PPARα, which may bring about syn-
ergistic activation in the presence of PGC-1α, whereas ERK-MAPK 
has the opposite effect. These signaling pathways transduce 
physiological stimuli, such as stress, fasting, and exercise, to the 
PGC-1α pathway. PGC-1α, in turn, coactivates transcriptional 
partners, including NRF-1 and -2, ERRα, and PPARα, which 
regulate mitochondrial biogenesis and FA-oxidation pathways. 
Dashed lines indicate activation mediated by signal transduction 
pathways in contrast to the coactivation by PGC-1α, which is 
denoted by solid lines. The arrows from ERRα to the NRFs and 
the PPAR complex indicate that ERRα activates these pathways 
at the level of expression.
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eration and increases coupled respiration and ATP content in 
numerous cell types via a cGMP-dependent pathway (58, 59). The 
effects of NO/cGMP appear to be mediated, at least in part, by 
transcriptional activation of PGC-1α expression levels (58).
Recent evidence has also implicated Ca2+ signaling in the 
control of the PGC-1α/PPARα regulatory pathway. Transgenic 
mice overexpressing constitutively active calcineurin (Cn) or 
Ca2+/calmodulin-dependent kinase (CaMK) in skeletal muscle 
displayed increased PGC-1α expression and expansion of slow-
twitch oxidative fibers and mitochondrial biogenesis (22, 60, 61). 
Activation of PGC-1α by Cn and CaMK is mediated transcrip-
tionally through myocyte enhancer factor-2 (MEF-2) and cAMP 
response element–binding protein (CREB), respectively (62). In 
the heart, exercise training activates the Cn and CaMK pathways 
coincident with maintained or enhanced mitochondrial func-
tion; however, paradoxically, overexpression of constitutively 
activated forms of Cn or CaMK results in reduced mitochondrial 
oxidation and heart failure (63–65). Recent studies have shown 
that Cn and CaMK both activate PGC-1α expression in cardiac 
myocytes but have distinct effects on downstream targets of the 
PGC-1α pathway (66). CaMK activates genes involved in glucose 
oxidation and mitochondrial electron transport while Cn selec-
tively activates mitochondrial FAO enzyme genes. The selective 
effects of Cn are thought to be mediated, in part, through direct 
transcriptional activation of the PPARα gene. Consistent with 
the gain-of-function results, reduction in Cn catalytic activity 
through cardiac-specific deletion of the CnB regulatory subunit 
results in reduced PGC-1α and PPARα expression and downreg-
ulation of FAO enzymes (66).
Perturbations in PGC-1/PPAR signaling  
in the hypertrophied and failing heart
Numerous studies have demonstrated altered cardiac substrate 
preference in the hypertrophied and failing heart. However, the 
direction of the “fuel shifts” varies with the etiology and severity 
of ventricular dysfunction. Studies using animal models of ven-
tricular hypertrophy due to hypertension or 
imposed pressure overload have consistently 
demonstrated a myocardial shift from FAO 
toward glucose oxidation (67–72). Changes 
in gene expression in the hypertrophied 
heart, including downregulation of mito-
chondrial FAO enzymes, are consistent with 
the observed metabolic alterations (73, 74).
The results of studies of energy substrate 
shifts in the failing heart, particularly in 
humans, have not led to a clear conclu-
sion. Some investigators have shown that 
expression of FAO genes and correspond-
ing enzymatic activities are reduced in the 
failing rodent and human heart (70, 73, 75). 
Consistent with these findings, recent car-
diac positron emission tomography (PET) 
studies in humans have shown a shift away 
from FA utilization with hypertensive car-
diac hypertrophy and idiopathic cardio-
myopathy (76, 77). However, others have 
demonstrated the opposite metabolic pro-
file or no change in substrate utilization in 
humans and animal models of heart failure 
of mild-to-moderate severity (78–80). Animal models of failure 
induced by pacing or myocardial infarction show that earlier stages 
are not associated with a switch from FAs to glucose as the primary 
energy substrate. Dogs with moderate severity coronary microem-
bolism–induced heart failure exhibited FA and glucose uptake pat-
terns that were indistinguishable from those of controls (81). These 
apparent discrepancies have been attributed to both the severity of 
failure and temporal differences during the progressive remodeling 
that characterizes the transition to heart failure. The specific etiol-
ogy of the myocardial disease may also play an important role.
Significant progress has been made in delineating the gene 
regulatory events driving the reduction of myocardial FA utiliza-
tion in the hypertrophied, failing, and hypoxic heart. Given the 
importance of PPARα for the transcriptional control of cardiac 
lipid metabolism, this nuclear receptor has served as an impor-
tant focus for such studies. In rodent models of pressure overload 
hypertrophy, expression of PPARα and PGC-1α is reduced in the 
hypertrophied and failing heart and in hypertrophied cardiac 
myocytes in culture (82–87). Levels of the PPAR partner, RXRα, 
are also reduced in a canine pacing-induced model of heart failure 
and by hypoxia in cardiac myocytes (88, 89). Interestingly, a recip-
rocal induction of transcription factors, including chicken oval-
bumin upstream promoter-transcription factor (COUP-TF) and 
Sp1 and Sp3, which repress promoter activity of key FAO enzyme 
genes, is observed in hypertrophy and heart failure models and is 
thought to contribute to the reduction in myocardial FAO (82, 90). 
Moreover, PPARα activity is inhibited posttranslationally in the 
hypertrophied cardiac myocyte in culture through ERK-MAPK–
dependent phosphorylation (83). The results of these studies 
suggest that one key mechanism involved in the energy substrate 
switches in the hypertrophied and failing heart involves deactiva-
tion of the PGC-1α/PPARα complex at both transcriptional and 
posttranscriptional levels (Figure 3).
In contrast to heart failure related to pressure overload or isch-
emia, the cardiomyopathy that develops in the context of insulin 
resistance and frank diabetes is associated with increased cardiac 
Figure 3
Cardiac energy substrate selection is a dynamic balance influenced by developmental, physi-
ological, and pathological cues. In the fetal heart, glucose oxidation is favored, whereas FA 
oxidation serves as the major ATP-generating pathway in the adult myocardium. Significant shifts 
in substrate preference occur in response to dietary (insulin) and physiological (exercise) stimuli. 
Certain pathophysiological contexts, such as hypertrophy and ischemia, drive metabolism toward 
glucose utilization, whereas in uncontrolled diabetes, the heart utilizes FAs almost exclusively. 
In some cases, as in early response to pressure overload–induced hypertrophy, these meta-
bolic shifts are thought to be protective. Alterations in activity or expression of nuclear receptors 
(PPARs and ERRs) and PGC-1α mediate these shifts in energy substrate utilization.
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reliance on FAs as the primary energy substrate (Figure 3) (91–94). 
This fuel switch is linked to the combined effects of myocyte insu-
lin resistance and high-circulating free FAs. We have found that, 
consistent with this metabolic profile, the expression and activity 
of PPARα, PGC-1α, and the enzymes of mitochondrial FAO are 
induced in both insulin-deficient and insulin-resistant forms of 
diabetes in mouse models (95, 96). The mechanism involved in the 
activation of PPARα signaling in the diabetic heart is unknown 
but likely involves increased cellular import of FAs, which serve as 
ligands for this nuclear receptor. In contrast, other studies have 
demonstrated a reduction in PPARα transcript levels in diabetic 
myocardium (97, 98). This apparent discrepancy could reflect tem-
poral-dependent regulatory events during progression of diabetic 
myocardial disease. Future studies aimed at defining the precise 
time-course of PPARα-driven regulatory events during the devel-
opment of diabetic cardiomyopathy are needed.
Do derangements in mitochondrial energy  
metabolism cause heart failure?
Myocardial fuel shifts as a cause of heart failure. Do deactivation of PGC-1α/ 
PPARα and the switch away from FAO in the hypertrophied heart 
contribute to the pathological remodeling that leads to heart failure? 
Similarly, does chronic activation of PPARα and myocardial FAO in 
the diabetic heart lead to cardiac dysfunction? Alternatively, do these 
myocardial substrate shifts serve adaptive functions in the diseased 
heart? The answers to these questions have not been resolved, but 
evidence provided largely by observations in rare genetic human dis-
eases and genetically modified mice offers some insight. However, 
perhaps the strongest evidence supporting deleterious effects of 
reduced capacity for cardiac FA utilization comes from the obser-
vations of the cardiac phenotype of human genetic defects in FAO 
pathway enzymes. Children with deficiencies in enzymes involved in 
mitochondrial long-chain FAO often develop a stress-induced car-
diomyopathy associated with myocardial lipid accumulation (99). In 
addition, mouse models in which the FAO enzymes, very-long-chain 
acyl-CoA dehydrogenase (VLCAD) or long-chain acyl-CoA dehy-
drogenase (LCAD), have been disrupted exhibit cardiomyopathies 
similar to that observed in humans (100, 101). Furthermore, the 
cardiomyopathic phenotype of mice with cardiac-specific deletion 
of the PPARβ gene also supports the conclusion that a reduction in 
capacity to oxidize FAs in the heart has deleterious effects (44). The 
PPARβ–/– hearts accumulate lipids in association with the develop-
ment of cardiac hypertrophy, which ultimately leads to dilated car-
diomyopathy, myocyte apoptosis, and death.
One proposed mechanism for cardiac dysfunction in these models 
is excess intracellular lipid accumulation resulting in myocyte dys-
function or death, termed “lipotoxicity” (reviewed in ref. 102). The 
heart and other high-energy flux organs are adapted to closely match 
energy substrate import and utilization, not storage. A mismatch can 
result from increased lipid delivery, such as occurs in obesity or dia-
betes, or impaired FA oxidation, as in the aforementioned models. 
The resulting derangements in cellular lipid homeostasis can lead to 
accumulation of lipid intermediates such as acyl-CoA thioesters, acyl-
carnitines, ceramides, and triglycerides, molecules that could confer 
cellular toxicity. Transgenic models in which proteins involved in FA 
uptake/delivery are overexpressed also exhibit lipid accumulation 
and systolic dysfunction (103, 104). These hearts display evidence of 
myocyte dropout due to activation of apoptotic pathways. Indeed, 
direct treatment with saturated long-chain FAs has been shown to 
trigger apoptosis in cardiac myocytes as well as in other cell types in 
culture via mechanisms that may involve generation of reactive oxy-
gen species (105–107). Collectively, observations in mice and humans 
indicate that severe reduction in mitochondrial FAO capacity sets the 
stage for cardiac lipotoxic effects related to lipid intermediates that 
accumulate in the context of impaired catabolism.
Despite compelling evidence for the deleterious effects of 
reduced mitochondrial FAO in genetic models and human defi-
ciency states, there is some data to suggest that a shift from FAO 
to glucose utilization in the hypertrophied heart may be adaptive, 
at least in the short term. Taegtmeyer and coworkers have shown 
that reactivation of FAO in a rat ventricular-pressure overload 
model causes ventricular dysfunction (108). In addition, despite 
reduced cardiac FAO rates, PPARα-null mice do not exhibit 
overt ventricular dysfunction (39). It is likely that the degree and 
duration of the pathophysiological stimulus as well as the sys-
temic metabolic state (e.g., levels of circulating lipids) ultimately 
determine whether alterations in FAO capacity contribute to the 
pathogenesis of heart failure.
As described above, the insulin resistant and diabetic heart 
is characterized by increased FAO rates due, perhaps in part, 
to chronic activation of the PPARα gene regulatory pathway. 
Studies of mice genetically modified to mimic the metabolic 
derangements of the diabetic heart have provided evidence that 
chronically increased reliance on FAs for energy leads to patho-
logical signatures of the diabetic heart. Mice with cardiac-specific 
overexpression of PPARα (MHC-PPARα mice) exhibit increased 
expression of PPARα target genes involved in cellular FA import 
and peroxisomal and mitochondrial FAO, coincident with lipid 
accumulation and increased rates of FAO (96, 109). Interestingly, 
myocardial glucose uptake and oxidation rates are reciprocally 
decreased in the MHC-PPARα mouse, a metabolic phenotype that 
mimics the diabetic heart. These results demonstrate that a prima-
ry drive on the PPARα gene regulatory pathway triggers cross-talk 
suppression of glucose utilization pathways. Importantly, the met-
abolic derangements of MHC-PPARα mice are associated with ven-
tricular diastolic/systolic dysfunction at baseline, which becomes 
more severe in the context of increased delivery of FAs to the heart 
such as occurs with high-fat feeding or insulinopenia (95). Thus, 
restricting the heart to reliance on FAs to the virtual exclusion of 
glucose oxidation leads to development of cardiomyopathy (109).
The metabolic dysregulation in the MHC-PPARα heart is associ-
ated with neutral lipid accumulation and increased production of 
reactive species consistent with the importance of oxidative stress 
and mitochondrial dysfunction in diabetic cardiomyopathy (95). 
Direct characterization of mitochondria from hearts in type 1 dia-
betic models has revealed evidence of damaged mitochondria and 
impaired mitochondrial respiration, presumably due to oxidative 
stress (110). In the same type 1 model, overexpression of antioxi-
dant proteins such as metallothionein and catalase reduced reac-
tive oxygen species and rescued cardiac contractility (111–113). A 
similar effect was observed with catalase overexpression in a mouse 
model of type 2 diabetes (112). The observations from elevated FA 
flux and FAO-deficient states, which indicate that either a chronic 
increase (diabetes) or decrease (pressure overload hypertrophy) in 
myocardial FAO can lead to heart failure, emphasize the importance 
of substrate flexibility for normal cardiac function (Figure 3).
Derangements in mitochondrial ATP generation. Evidence for a link 
between mitochondrial respiratory dysfunction and heart fail-
ure is compelling. The cardiomyopathic phenotype of humans 
with mitochondrial genome defects underscores the importance 
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of high-capacity mitochondrial ATP production for normal 
striated-muscle function. Mutations in both nuclear- and mito-
chondrial-encoded genes account for heritable respiratory chain 
defects (for an extensive review of this topic, see refs. 114–117). 
Respiratory chain defects typically present as multisystem dys-
function disproportionately affecting organs with high ATP 
demand, such as the heart, skeletal muscle, and the central ner-
vous system. Cardiomyopathy may develop during childhood 
or at later ages. Mouse models of mitochondrial dysfunction 
have also provided important information about the role of 
mitochondrial proteins in regulating mitochondrial number 
and function as well as the way in which altered mitochondrial 
energetics contribute to the development of heart failure. Tfam 
is a nuclear-encoded mitochondrial transcription factor neces-
sary for mitochondrial biogenesis and gene expression. Cardiac-
specific Tfam–/– mice exhibit reduced respiratory capacity and 
mitochondrial DNA in the heart before birth coincident with a 
high neonatal mortality (118). Surviving animals develop hyper-
trophy, progressing to dilated cardiomyopathy and conduction 
abnormalities, and die by 4 months of age. Interestingly, cardiac 
dysfunction is accompanied by a metabolic shift from FAO to 
glucose oxidation (119).
Adenine nucleotide translocators (Ants) are mitochondrial-mem-
brane proteins involved in the transport of cytoplasmic ADP in 
exchange for mitochondrial ATP, so mitochondria deficient in Ant 
have reduced capacity for substrate level phosphorylation. Mice 
targeted for the Ant1 gene, the cardiac/skeletal muscle expressed 
isoform, exhibit reduced ADP-dependent respiration rates in heart 
and skeletal muscle in spite of increased mitochondrial number 
(120, 121). The mitochondrial proliferation is likely a compensa-
tory response to cellular energy deficiency but is thought to con-
tribute to progressive cardiac hypertrophy that develops in these 
mice (121, 122). ATP deficiency is thought to be a primary cause 
for the observed pathophysiology, but these models also support a 
role for mitochondrial-derived ROS in mediating cellular damage 
(123). Although the precise cellular insults are still unknown, these 
genetic models demonstrate that mitochondrial dysfunction is suf-
ficient for the development of heart failure.
Several recently developed mouse models have identified exciting 
potential links between PGC-1α–mediated control of mitochondri-
al function and the development of heart failure. Sano et al. recent-
ly found that overexpression of cyclin T/Cdk9, an RNA polymerase 
kinase, triggers cardiac hypertrophy (124). Further studies revealed 
that in the context of ventricular pressure overload, mice overex-
pressing Cdk9 in the heart develop a fulminant apoptotic cardio-
myopathy (125). Gene expression–profiling studies demonstrated 
that Cdk9 suppresses expression of PGC-1α and its downstream 
targets involved in mitochondrial respiratory function. Rescue of 
PGC-1α expression in cardiac myocytes in culture prevented Cdk9-
triggered apoptosis. In a separate mouse model, chronic activation 
of PGC-1α in the heart, as occurs in diabetes, led to ventricular dys-
function. In a study using an inducible, cardiac-specific transgenic 
system, chronic overexpression of PGC-1α protein in the adult 
mouse heart caused mitochondrial ultrastructural abnormalities 
and reduced myofibrillar density, which led to cardiomyopathy 
and diastolic dysfunction (25). Interestingly, the mitochondrial 
proliferative response is reversible and the cardiomyopathy rescued 
upon cessation of transgene expression. The basis for this revers-
ible cardiomyopathy is unknown but could involve the accumula-
tion of reactive intermediates or abnormalities in ATP generation. 
Taken together, these recent findings suggest that, in the context 
of a mechanical stress such as pressure overload, reduced levels of 
PGC-1α predispose the heart to pathological remodeling related 
to mitochondrial dysfunction and apoptosis. Conversely, chronic 
activation of PGC-1α and its downstream targets, such as PPARα, 
that mimic the diabetic state also leads to ventricular dysfunction 
through mechanisms that are reversible.
Despite strong evidence for a link between mitochondrial dys-
function and heart failure in genetic models, the role of altered 
mitochondrial ATP generation in the pathogenesis of acquired 
forms of heart failure is less clear. Phosphocreatine (pCR) serves 
as the main energy store in myocardium (for review, see ref. S1; 
see Supplemental References; supplemental material available 
online with this article; doi:10.1172/JCI200524405DS1). Early 
studies revealed that myocardial pCR/ATP ratios are reduced in 
the hypertrophied and failing heart while absolute ATP levels are 
only detectably reduced in heart failure (S2–S4). However, the 
concentration of ATP measured in the failing myocardium is still 
above the Km for most cellular ATPases. Consistent with a gradu-
al fall in intracellular high-energy phosphates, the “energy sensor 
kinase,” AMP-activated protein kinase (AMPK), is upregulated 
and activated during hypertrophy (S5). These results suggest that 
myocardial energy reserves are disproportionately reduced during 
hypertrophy and heart failure progression compared to absolute 
ATP levels. In dog models of pacing-induced heart failure, ATP 
concentrations fall gradually coincident with a reduction in mito-
chondrial respiration rates during the progression to heart failure 
(S6, S7). These functional changes are associated with evidence of 
structural abnormalities in mitochondria from these hearts (S8). 
Reduced mitochondrial oxidative capacity has also been observed 
in rodent heart failure models (87). Further studies will be neces-
sary to accurately delineate the temporal pattern of alterations 
in bioenergetics during the development of heart failure. Murine 
genetic loss-of-function and pharmacological rescue strategies in 
larger animal models should serve as useful experimental strate-
gies to determine cause-and-effect relationships.
Metabolic modulators as a new treatment strategy  
for heart failure? A question of balance
In summary, evidence is emerging to support the concept that 
alterations in myocardial fuel selection and energetics are linked 
to the development and progression of heart failure. Accordingly, 
metabolic pathways involved in cardiac FA and glucose utiliza-
tion or ATP generation are attractive targets of novel therapeutic 
strategies aimed at the prevention or early treatment of heart fail-
ure. Indeed, specific activators for each of the PPARs have been 
developed and are currently used for treatment of hyperlipidemia 
(e.g., fibrates) and diabetes (thiazolidinediones). Activation of the 
PPAR pathway in heart or extracardiac tissues, such as adipose or 
liver, could theoretically reduce cardiac lipotoxicity by reducing 
lipid delivery or increasing mitochondrial oxidation. However, 
a strong word of caution is necessary. As described above, it is 
now clear that the degree of metabolic modulation is an impor-
tant determinant of whether shifts in energy substrate utilization 
serve adaptive or maladaptive functions in the context of dis-
ease states that predispose patients to heart failure. Conversely, 
chronic activation of PPARα could lead to deleterious effects, par-
ticularly in the context of diabetes, hyperlipidemic states, or the 
ischemic heart, given the potential for increased mitochondrial 
oxidative flux, which could generate ROS and increase oxygen 
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consumption. It is likely that the response will be disease-specific 
and dependent on the systemic metabolic phenotype. Studies in 
large animals and humans will be particularly informative. Such 
studies will require rigorous metabolic phenotyping approaches 
with imaging modalities such as PET and spectroscopy to define 
baseline myocardial substrate utilization and energetic profiles, 
respectively. Similarly, both metabolic and functional endpoints 
will be necessary to assess response to therapy. If metabolic modu-
lator therapy proves useful, the standard diagnostic approach to 
the heart failure patient will likely include metabolic imaging or 
surrogate metabolic biomarkers to guide therapeutic decisions 
and assess the patient’s response. In this regard, an interdisciplin-
ary approach involving cardiologists, endocrinologists, and radi-
ologists might be envisioned.
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